Skip to main content
OpenTrials
Completed

NCT Number: NCT00365885

Showing Health Information Value in a Community Network

The purpose of this study is to determine the value of shared health information on care quality and costs when this information is used to notify care providers about concerning health events for patients cared for by a community-based network of providers.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Duke University Medical Center

Durham, North Carolina, 27710, United States

About this study

Project Abstract This three-year project will assess the costs and benefits of health information technology (HIT) in an established community-wide network of academic, private and public healthcare facilities created to share clinical information for the purpose of population-based care management of over 16,000 Medicaid beneficiaries in Durham County, North Carolina. The area of interest for this project is the impact of information-driven interventions on care quality, patient safety and healthcare costs across the diverse stakeholders participating in this collaborative partnership. In order to asses HIT value rigorously in the context of a production information system that is under continual development, we propose to conduct a randomized controlled trial. Specifically, we will randomly assign patients by family unit to either a control group or to an intervention group in which they will initially receive one of 3 information-driven interventions. The interventions include clinical alerts sent to care providers, performance feedback reports presented to clinic managers, and care reminders sent directly to patients. The content of the interventions will address "concerning" events (e.g., an emergency room encounter for asthma) and care deficiencies (e.g., delinquency on biannual mammogram) identified from the composite set of clinical data in our information system. To assess the benefits and burdens of the interventions, combinations of the 3 interventions will be sequentially introduced into the study groups over the course of the project. The analysis will compare groups receiving various combinations of interventions as well as those receiving no interventions. At baseline and at six-month intervals throughout the course of the study, we will measure emergency department encounter rates, hospitalization rates, HEDIS (Healthcare Effectiveness Data and Information Set) scores, missed appointment rates, glycated hemoglobin levels in diabetics, and patient satisfaction. Our assessment will look at the societal value of HIT as well as the value for individual stakeholders including patients, providers, payers, purchasers and policy makers. From these measures, we will assess the costs and benefits of this community-wide effort to promote interoperability of clinical data exchange in order to increase the understanding of HIT value in a community setting. In our preliminary studies, we have observed a statistically significant 3-fold reduction in repeat ED (Emergency Department) encounter rates using email alerts alone. The approach used in this project is able to be generalized across geographic areas and healthcare settings and can, therefore, serve to promote the dissemination of HIT to other communities.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Enrollment in the Community Care of North Carolina Medicaid program in Durham County North Carolina

Exclusion criteria

-

Treatment and study plan

Computer-based clinical decision support.

Other

computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients

Other names: Decision support engine is called SEBASTIAN

Primary outcomes

  1. Emergency department utilization rates and hospitalization rates

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

Secondary outcomes

  1. ED encounter rates for low severity conditions

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  2. ED encounter rates for asthma

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  3. ED encounter rates for diabetes

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  4. Hospitalization rates

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  5. Hospitalization rates for asthma (also PQI)

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  6. Hospitalization rates for diabetes (also PQI)

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  7. Glycemic control (hemoglobin A1c)

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  8. Medication contraindications

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  9. HEDIS - Preventive services

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  10. HEDIS - # WCC visits

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  11. AHRQ Prevention Quality Indicators

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  12. HEDIS - Asthma and diabetes

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  13. # of messages triggered for health risks

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  14. # of messages triggered for barriers to care

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  15. Missed appointment rates

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  16. Primary care appointment rates

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  17. F/U rates post-partum

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  18. Patient satisfaction instruments (CHAPS)

    Time frame: at 6 to 9 months after the intervention has been introduced and then at 3 to 6-month intervals as the intervention is sequentially enhanced.

  19. EuroQoL

    Time frame: at 6 to 9 months after the intervention has been introduced and then at 3 to 6-month intervals as the intervention is sequentially enhanced.

  20. Provider opinion surveys

    Time frame: At conclusion of study

  21. Costs of ED utilization for all causes

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  22. Costs of ED use for asthma

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  23. Costs of ED use for diabetes

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  24. Costs of ED use for low severity visits

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  25. Hospitalization costs for all causes

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  26. Hospitalization costs for asthma

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  27. Hospitalization costs for diabetes

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  28. Reimbursement for labs+other ancillary services

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  29. Primary care reimbursement

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

  30. ED rates for recurrent ED encounters

    Time frame: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

Sponsors and collaborators

Lead sponsor

Duke University

Other

Registry information

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Aug 18, 2006
Registry last updated
Jul 11, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.